Cardinal Health Leverages Specialty Surge to Raise FY26 Outlook Amid Tariff Uncertainty

“Another strong quarter,” CEO Jason Hollar said, underscoring a narrative that the company’s core and growth engines are both delivering “durability and resilience.” Total revenue climbed 11% year‑over‑year to $61 billion, driven primarily by the **Pharmaceutical and Specialty Solutions** segment, which posted $56.1 billion in sales, and the **Other** segment, which surged 31% to $1.7 billion. Gross profit rose 18% to $2.5 billion, while enterprise operating earnings jumped 18% to $956 million.

The headline earnings beat was powered by a 35% rise in non‑GAAP EPS to $3.17, reflecting a blend of higher volumes, disciplined cost management and a “discrete tax planning benefit” that drove the effective tax rate down to 10.2% for the quarter.

Adjusted free cash flow hit $1.7 billion, and the balance sheet now holds nearly $4 billion in cash, with leverage trimmed to a Moody’s‑adjusted 3.0×, comfortably inside the 2.75‑3.25× target range. Share repurchases accelerated, adding $250 million in the quarter and bringing total FY26 buy‑backs to $1 billion—$250 million above the baseline target.

**Pharma’s mixed dynamics** Pharma revenue grew 11% but was “offset by a 6‑percentage‑point impact from inflation‑reduction at WAC pricing adjustments,” Hollar noted. GLP‑1 products still delivered “over 30%” growth, albeit slower than the prior quarter, contributing 6 points to revenue expansion. Meanwhile, IRA‑related pricing changes shaved another 6 points, leaving net growth unchanged. Despite the mix turbulence, segment profit outpaced revenue, rising 18% to $784 million, buoyed by brand and specialty contributions.

**Specialty’s acceleration** Specialty revenue surged more than 20% in Q3, positioning the business to exceed $50 billion for FY26. The company highlighted “over‑20% revenue growth” and a “above‑market” trajectory, driven by recent acquisitions (Solaris, GIA, ION) and the expanding **Specialty Alliance** MSO platform.

Hollar said the firm is “prioritizing autoimmune and urology” for future bolt‑on deals, while CFO Aaron Alt stressed that SG&A, after stripping M&A effects, grew only 7%—a “purposeful” investment in technology and talent to sustain the specialty momentum.

**GMPD’s modest performance** The **General Merchandise Pharmaceutical Distribution (GMPD)** segment posted flat revenue at $3.1 billion, with profit slipping to $25 million due to “adverse net impact of tariffs.” The company is still awaiting a Supreme Court‑mandated refund on $200 million of IEPA tariffs; management estimates a potential net benefit of roughly $100 million, but has not booked any impact.

Hollar emphasized that the segment’s “simplification strategy” is on track, with the Cardinal Health brand growing “mid‑single digits for five consecutive quarters.”

**Other growth engines** At‑Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics together delivered $179 million in profit, a 34% rise. The ADS acquisition is now fully integrated, adding roughly 1,000 employees and half‑million patients, while Nuclear’s Actinium‑225 capacity expansion positions the business for “rapidly growing demand for novel targeted cancer therapies.”

**Guidance lift and outlook** Buoyed by the quarter’s performance, Cardinal Health raised its FY26 non‑GAAP EPS outlook to $10.70‑$10.80, a $0.50 midpoint increase, and widened adjusted free‑cash‑flow guidance to $3.3‑$3.7 billion.

Pharma revenue is now expected at the lower end of the 15%‑17% growth range, while specialty revenue is projected to stay above $50 billion. GMPD revenue guidance remains 1%‑3% growth, with profit held at $150 million. The “Other” segment is forecast to grow 26%‑28% in revenue, with profit growth nudged up to 36%‑38%.

Management cautioned that the **Solaris** distribution volumes will only modestly affect FY26 results, as onboarding occurs late in the year, but the ramp is “a positive for next year.” They also reiterated that the tariff refund timeline remains uncertain, and that any upside would be shared with customers, potentially adding “about $100 million earnings gain” when realized.

**Analyst scrutiny** During Q&A, analysts pressed on the size of the SG&A acceleration, the potential gaps in the specialty portfolio, and the impact of IRA pricing on margins. Alt clarified that, excluding M&A, SG&A rose 7% and is “purposeful and disciplined.” Hollar acknowledged a focus on “autoimmune and urology” as the next inorganic targets.

Questions on fee‑for‑service pricing power prompted Hollar to assert that the company’s “service fees…should not change” and that the firm is “well‑positioned” to renegotiate if needed. Energy‑price concerns were also raised; Hollar responded that current oil‑related fuel costs are “much more manageable than the hyper‑inflationary environment of 2022,” and that exam‑glove price spikes affect less than 5% of the Cardinal‑branded portfolio.

**Market reaction** Despite the upbeat guidance, Cardinal Health’s stock slipped 4.9% in morning trade, extending a 5.78% weekly decline and a 5.91% year‑to‑date loss, leaving the share 17.4% below its 52‑week high of $233.20. The pullback reflects lingering concerns over tariff uncertainty and the modest revenue guidance for pharma, even as investors digest the stronger earnings and cash‑flow outlook.